LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.48 -4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.48

Máximo

0.51

Métricas clave
By Trading Economics
Ingresos	-9.9M -48M
Ventas	1.8M 13M
Margen de beneficios	-362.728
Empleados	144
EBITDA	-10M -45M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+623.53% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-418M 129M
Apertura anterior	4.48
Cierre anterior	0.48

Noticias sobre sentimiento de mercado

By Acuity

100%

333 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 mar 2026, 19:18 UTC

Principales Movimientos del Mercado

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Charlas de Mercado

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Charlas de Mercado

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Charlas de Mercado

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Ganancias

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Ganancias

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Ganancias

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Ganancias

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Noticias de Eventos Importantes

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Ganancias

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Noticias de Eventos Importantes

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Adquisiciones, fusiones, absorciones

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Noticias de Eventos Importantes

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

623.53% repunte

Estimación a 12 Meses

Media 3.69 USD 623.53%

Máximo 15 USD

Mínimo 0.3 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

333 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.